

What is claimed is:

1. A method of inducing immune tolerance to a graft in a recipient, comprising:
 - (a) administering to the recipient an immunotoxin, thereby reducing the recipient's T-cell population; and
 - (b) administering to the recipient an agent that inhibits dendritic cell maturation.
2. The method of claim 1, wherein the graft is selected from the group consisting of kidney, liver, heart, pancreas, lung, skin, and isolated cell transplants of pancreatic islets, hepatocytes, stem cell precursors, and differentiated stem cell precursors.
3. The method of claim 1, wherein the agent that inhibits dendritic cell maturation is an inhibitor of nuclear translocation of NfκB.
4. The method of claim 3, wherein the inhibitor of nuclear translocation of NfκB is an analog or derivative of deoxyspergualin.
5. The method of claim 1, wherein the agent that inhibits dendritic cell maturation activates one or more NF-AT dependent Th2 cytokines.
6. The method of claim 1, wherein the agent that inhibits dendritic cell maturation inhibits one or more NfκB dependent Th1 cytokines.
7. The method of claim 1, wherein the inhibitor of dendritic cell maturation is a soluble IL-17 receptor Fc fusion protein.

8. The method of claim 1, wherein the inhibitor of dendritic cell maturation is a glucocorticoid.
9. The method of claim 1, wherein the inhibitor of dendritic cell maturation is a blocker of tumor necrosis factor alpha binding.
10. The method of claim 1, wherein the inhibitor of dendritic cell maturation is a blocker of granulocyte macrophage colony stimulating factor binding.
11. The method of claim 1, wherein the inhibitor of dendritic cell maturation is a blocker of IL-12p70 binding.
12. The method of claim 1, wherein the inhibitor of dendritic cell maturation is a blocker of interleukin 1 β binding.
13. The method of claim 1, wherein the inhibitor of dendritic cell maturation is anti-CD154 ligand.
14. The method of claim 1, wherein the agent that inhibits dendritic cell maturation is administered to the recipient at least once.
15. The method of claim 1, wherein the agent that inhibits dendritic cell maturation is administered to the recipient prior to transplantation.
16. The method of claim 1, wherein the immunotoxin is an anti-T cell immunotoxin directed at the CD3 epitope.
17. The method of claim 1, further comprising administering to a transplant donor, prior to harvesting the transplant, an agent that inhibits dendritic cell maturation.

18. A method of screening for an agent that acts synergistically with an immunotoxin in inducing immune tolerance, comprising:
 - (a) transplanting a donor graft to a recipient;
 - (b) administering to the recipient an immunotoxin, thereby reducing the recipient's T-cell population;
 - (c) administering to the recipient the agent to be screened;
 - (d) obtaining a dendritic cell-containing sample; and
 - (e) determining a percentage of the dendritic cells in the sample that express or can be induced to express a marker specific for mature dendritic cells, wherein a low percentage shows a synergistic action.
19. A method of screening for an agent that inhibits dendritic cell maturation, comprising:
 - (a) obtaining a population of immature dendritic cells from a dendritic cell-containing sample of a subject;
 - (b) culturing the population of cells in the presence of the agent to be screened; and
 - (c) determining a percentage of dendritic cells that express or can be induced to express a marker specific for mature dendritic cells, wherein a low percentage shows inhibition of dendritic cell maturation.
20. A composition comprising an immunotoxin and an agent that inhibits dendritic cell maturation.

21. The composition of claim 18, wherein the immunotoxin is an anti-T cell immunotoxin directed at the CD3 epitope.
22. The composition of claim 19, wherein the agent that inhibits dendritic cell maturation is an inhibitor of nuclear translocation of NfκB.
23. The composition of claim 19, wherein the agent that inhibits dendritic cell maturation activates one or more NF-AT dependent Th2 cytokines.
24. The composition of claim 19, wherein the agent that inhibits dendritic cell maturation inhibits one or more NfκB dependent Th1 cytokines.